Abstract | PURPOSE: PATIENTS AND METHODS: Plasma estradiol and estrone sulfate levels from a highly sensitive radioimmunoassay were available for 44 postmenopausal patients who received anastrozole (1 mg per day) for 3 months followed by letrozole (2.5 mg per day) for 3 months or the opposite sequence. Correlations between the estrogen suppression by each AI and BMI were assessed. RESULTS: Baseline values of estradiol and estrone sulfate were significantly correlated with BMI (r = 0.57; P < .001, and r = 0.38; P = .006, respectively). Levels of estrogen in patients receiving treatment were greater at higher levels of BMI with both AIs, but although this was significant with letrozole (r = 0.35; P = .013, and r = 0.30; P = .035 for estradiol and estrone sulfate, respectively), it was not with anastrozole. Suppression of both estrogen types was greater with letrozole across the full range of BMIs in this study. CONCLUSION:
|
Authors | Elizabeth J Folkerd, J Michael Dixon, Lorna Renshaw, Roger P A'Hern, Mitch Dowsett |
Journal | Journal of clinical oncology : official journal of the American Society of Clinical Oncology
(J Clin Oncol)
Vol. 30
Issue 24
Pg. 2977-80
(Aug 20 2012)
ISSN: 1527-7755 [Electronic] United States |
PMID | 22802308
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Antineoplastic Agents, Hormonal
- Aromatase Inhibitors
- Estrogens
- Nitriles
- Triazoles
- Estrone
- Anastrozole
- Letrozole
- estrone sulfate
|
Topics |
- Aged
- Aged, 80 and over
- Anastrozole
- Antineoplastic Agents, Hormonal
(administration & dosage, pharmacology)
- Aromatase Inhibitors
(administration & dosage, pharmacology)
- Body Mass Index
- Breast Neoplasms
(blood, drug therapy)
- Estrogens
(blood)
- Estrone
(analogs & derivatives, blood)
- Female
- Humans
- Letrozole
- Middle Aged
- Neoplasms, Hormone-Dependent
(blood, drug therapy)
- Nitriles
(administration & dosage, pharmacology)
- Postmenopause
- Triazoles
(administration & dosage, pharmacology)
|